Androgen Insensitivity Syndrome Market

Market Overview:

The 7 major androgen insensitivity syndrome markets reached a value of US$ 378.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 633.1 Million by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.

The androgen insensitivity syndrome market has been comprehensively analyzed in IMARC's new report titled "Androgen Insensitivity Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Androgen insensitivity syndrome (AIS) refers to a rare genetic condition that affects sexual development and is characterized by varying degrees of insensitivity to male sex hormones, or androgens, in individuals with a male chromosomal pattern (XY). This condition causes mutations in the gene that codes for the androgen receptor, leading to the inability of cells to respond to androgens properly. The symptoms of the ailment may vary widely depending on the degree of severity. In complete AIS, individuals suffering from the illness may appear externally female, with underdeveloped or absent male reproductive structures while partial AIS might result in ambiguous genitalia or a mix of both male and female characteristics. Some patients might not even realize they have the condition until puberty, when the absence of menstruation becomes apparent. Diagnosis typically involves a combination of genetic testing to identify mutations in the androgen receptor gene and physical examinations to assess the external and internal genitalia.

The escalating incidences of genetic mutations affecting the androgen receptor's functionality are primarily driving the androgen insensitivity syndrome market. In addition to this, the inflating utilization of efficacious interventions, including hormone therapy, gonadectomy, and psychological support, to manage the condition and alleviate associated challenges, is also creating a positive outlook for the market. Moreover, the widespread adoption of genetic counseling and diagnostic advancements that help in facilitating early detection and personalized management strategies by better understanding and addressing the complex spectrum of AIS is further bolstering the market growth. Apart from this, the rising usage of reconstructive surgeries, which aim to modify or construct physical features and appearance aligned with the patient's identified gender, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of reproductive technologies, like in vitro fertilization with preimplantation genetic testing, that offers prospects for individuals suffering from AIS to achieve parenthood aspirations, is also augmenting the market growth. Furthermore, the increasing demand for genetic editing techniques, notably CRISPR-Cas9 technology, since they work by rectifying or modifying the faulty genes underpinning the condition, thereby improving the treatment outcomes, is expected to drive the androgen insensitivity syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the androgen insensitivity syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for androgen insensitivity syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the androgen insensitivity syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the androgen insensitivity syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the androgen insensitivity syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current androgen insensitivity syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the androgen insensitivity syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the androgen insensitivity syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the androgen insensitivity syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of androgen insensitivity syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of androgen insensitivity syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of androgen insensitivity syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with androgen insensitivity syndrome across the seven major markets?
• What is the size of the androgen insensitivity syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of androgen insensitivity syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Androgen Insensitivity Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for androgen insensitivity syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the androgen insensitivity syndrome market?
• What are the key regulatory events related to the androgen insensitivity syndrome market?
• What is the structure of clinical trial landscape by status related to the androgen insensitivity syndrome market?
• What is the structure of clinical trial landscape by phase related to the androgen insensitivity syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the androgen insensitivity syndrome market?